IVA Inventiva S.A. American Depository Shares

XNAS 3.83 Delayed
Find condors

Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Fibonacci levels Insider trading

Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.

IVA $3.83 —
Key stats
$3.83
52-Week Range
$2.82 – $7.29
YTD
-19.43%
Straddle Price
$4.03
P/C Vol Ratio
0.47
Market Cap
$0.9B
Open
$3.81
Day Range
$3.69 – $3.90
Volume
1,011,323
Prev Close
$3.80
Fair Value

A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.

  • DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
  • Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
  • DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 2% and dividend payments are stable — below that the dividend is a token payout and Gordon (which values only the dividend stream) systematically underprices growth names, so those route to DCF + comparables + market anchor instead.
  • P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
  • Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
  • Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
  • Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
  • Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
10-yr Treasury (rf)4.90%
Beta vs SPY0.91
Cost of Equity (CAPM)9.45% (VRP-adj)
WACC9.56%
Volatility Risk Premium+313.0pp (IV − HV30)
Effective Tax Rate21.0%
Rev. Growth (YoY, DCF input)+3.0%
DCF Horizon5 years explicit + fade
Forward Tilt (NTM/TTM)×1.03 (applied to P/E, EV/EBITDA, P/S)
Quality Score0/6 — cyclical/struggling (5y DCF)
SMA 50$3.73 (Market Anchor value)
SMA 20 / Bollinger Mid$3.48
Bollinger Width / SMA2041.4% (drives anchor stability)
Net Debt$0.0B
Market Cap$1B
Peers used for multiples: ABEO, ACHV, CLDX, CORT, DCTH, LLY, MIST, PHAT
Blended Fair Value
—
Deviation
—
MethodImplied PriceWeightDetail
DCF n/a 0%
DDM (Gordon) n/a 0%
Peer P/E n/a 0% median 47.8× · 3 peers
Peer EV/EBITDA n/a 0% median 27.1× · 3 peers
Peer P/B n/a 0% median 4.2× · 5 peers
Peer P/S n/a 0% median 8.8× · 7 peers
Market Anchor (SMA50) $3.73 0% stability 0% (BB-width)
Options Expected (B-L 30d) n/a 0%
As of 2026-11-09 · updated
About
Industry (SIC)
PHARMACEUTICAL PREPARATIONS (2834) · industry map
Exchange
XNAS
Market Cap
$0.9B
Employees
77
List Date
2020-07-10
CIK
0001756594
Homepage
https://www.inventivapharma.com

Inventiva SA is a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and other diseases with unmet medical needs.

Summary
—
composite
—
No summary data available for this symbol yet.

Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.

Chart
Seasonality
'21'22'23'24'25'26Avg
Jan2.08%-9.24%25.17%-19.05%13.34%29.41%6.95%
Feb0.81%1.36%-14.55%-4.23%24.80%9.81%3.00%
Mar-6.67%-7.84%-30.06%-10.45%-0.68%-11.76%-11.24%
Apr-7.09%-14.74%-23.60%-16.58%25.85%-5.52%-6.95%
May-7.45%-7.25%43.19%13.27%-3.14%-0.80%6.30%
Jun-0.33%-37.07%4.94%-20.05%-5.90%-20.75%-13.19%
Jul-5.35%-16.58%3.54%-21.46%12.25%22.24%-0.89%
Aug-2.22%1.35%-9.31%0.22%92.24%10.12%15.40%
Sep7.52%-10.61%14.75%-19.78%10.08%-22.64%-3.45%
Oct10.37%24.96%-6.15%49.44%-27.24%5.49%9.48%
Nov-11.33%-10.02%12.60%-3.64%3.66%0.13%*-1.43%
Dec0.81%2.53%4.54%-18.01%6.90%---0.65%
Total-19.19%-63.24%2.23%-60.90%208.63%2.45%11.66%
Technical Indicators

Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.

Trend Indicators
  • SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
  • EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
  • MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
  • ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
  • +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
  • RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
  • Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
  • Williams %R — inverted scale: <−80 oversold, >−20 overbought.

Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.

Volume & Volatility
  • Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
  • OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
  • Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
  • ATR / True Range — average daily $ move; sizing and stop-loss reference.
  • HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.

Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →

Trend Indicators

SMA 20: $3.52
SMA 50: $3.71
SMA 200: $4.80
Current: $3.83
EMA 12: $3.72
EMA 26: $3.64
MACD: 0.0737 | Signal: 0.0491
BULLISH
ADX (14): 28.97
TREND
+DI: 26.45
−DI: 14.74

Momentum Oscillators

RSI (14): 55.79
NEUTRAL
Stoch %K: 57.29
Stoch %D: 63.17
Williams %R: -42.65

Volume & Volatility

BB Upper: $4.23
BB Lower: $2.80
NEUTRAL
OBV: 5,648,094
Vol SMA 20: 2,813,758
Vol ROC: -69.70%
ATR: $0.27
True Range: $0.21
HV 20: 77.0%
HV 30: 80.1%
HV 60: 65.5%

Data Summary

Data Points: 500
Last Updated:
Date Range: 2024-11-07T00:00:00 – 2026-11-06T00:00:00
AI Analysis

IVA (Inventiva) - Comprehensive Stock Analysis Report

Executive Summary

Overall Assessment: BEARISH with Confidence Level 7/10

Key Drivers & Primary Risks:

  • Severe technical deterioration with price 41.8% below 200-day MA, all moving averages in bearish alignment
  • Extreme oversold conditions (RSI 27.72, Stochastic %K 3.21, Williams %R -99.51) suggesting capitulation selling
  • Positive financing news (€130M funding, debt restructuring) fundamentally contradicts severe technical breakdown
  • Exceptionally high implied volatility (418.9% current IV, 554.1% IV premium vs realized) indicates extreme uncertainty

Investment Thesis: Inventiva faces a critical inflection point between fundamentally supportive news (Phase 3 financing secured, debt refinancing) and a technical collapse suggesting severe loss of investor confidence. The extreme oversold readings and elevated volatility create both significant downside risk if support fails and potential capitulation reversal opportunity if institutional accumulation begins. The 2.71 put/call volume ratio reflects panic selling that may be pricing in existential concerns beyond the financing announcements.

Recent News Sentiment Impact: Positive news (€130M financing on 2026-06-16 and debt restructuring on 2026-06-12) has failed to arrest price decline, suggesting market skepticism about funding adequacy, dilution concerns, or underlying clinical/commercial viability issues not disclosed in headlines.

Technical Analysis

Trend Direction

  • Short-term (1-4 weeks): BEARISH DOWNTREND — Price $2.90 trading 15.9% below SMA 20 ($3.45), below all key moving averages, ADX 27.85 confirming strong downtrend regime
  • Medium-term (1-3 months): SEVERE BEARISH — Price 30.1% below SMA 50 ($4.15), technical structure completely deteriorated
  • Long-term (3-12 months): BEARISH — Price 41.8% below SMA 200 ($4.98), suggesting multi-month liquidation or fundamental repricing

Support/Resistance Levels

| Level | Type | Significance | |-------|------|---| | $2.99 | Support | Bollinger Band lower band (critical near-term floor) | | $2.90 | Current | Trading at Bollinger Band lower edge — extreme position | | $3.45 | Resistance | SMA 20, Bollinger Band middle (first recovery target) | | $3.91 | Resistance | Bollinger Band upper band (secondary recovery target) | | $4.15 | Resistance | SMA 50 (medium-term recovery level) | | $4.98 | Resistance | SMA 200 (long-term moving average recovery) |

Critical Support Breakdown Risk: Price trading at lower Bollinger Band edge with Williams %R at -99.51 suggests any breakdown below $2.99 could trigger accelerated selling with next support unclear (potential gap down scenario).

Momentum Signals

RSI (14): 27.72 — OVERSOLD

  • Extreme oversold reading (<30) typically signals capitulation selling and potential reversal point
  • However, oversold conditions can persist in deteriorating trends; requires confirmation from other indicators
  • RSI divergence analysis unavailable but magnitude suggests exhaustion selling

MACD: -0.29 / Signal: -0.02 / Histogram: -0.27 — BEARISH

  • MACD below signal line with negative histogram confirming bearish momentum
  • No bullish crossover signal present; histogram widening would indicate accelerating bearish momentum
  • Classic late-stage downtrend configuration

Stochastic Oscillator: %K 3.21 / %D 12.18 — EXTREME OVERSOLD

  • %K at 3.21 (well below 20 oversold threshold) represents one of most extreme readings possible
  • %D at 12.18 also deeply oversold; extreme divergence between the two suggests recent sharp selloff
  • High probability of mean reversion bounce, though timing uncertain in downtrends

Bollinger Bands: OVERSOLD SQUEEZE POSITION

  • Price $2.90 trading 0.37% above lower band ($2.99)
  • Bollinger Band Width 26.60% (moderate bandwidth, not extreme squeeze)
  • Position at lower band historically suggests mean reversion potential to middle band ($3.45, +19% from current)

Volume Analysis

Concerning Volume Deterioration:

  • Volume SMA 20: 2,718,569 shares
  • Volume Rate of Change: -73.83% (volume has collapsed 73.83% vs 20-day average)
  • On-Balance Volume: -4,758,377.87 — Deeply negative, indicating persistent net selling pressure over accumulation

Interpretation: The collapse in volume (-73.83% rate of change) combined with deeply negative OBV suggests:

  1. Recent volume spike down (capitulation selloff) followed by dried-up volume
  2. Lack of buying interest at current levels despite oversold technicals
  3. Potential institutional liquidation without matching institutional accumulation
  4. High risk that any bounce will face selling pressure if volume remains depressed

Institutional Activity Signal: Low current volume + deeply negative OBV suggests institutions may still be exiting positions rather than accumulating at oversold levels.

News & Sentiment Analysis

Recent Headlines Summary

| Date | Headline | Theme | Sentiment | |------|----------|-------|-----------| | 2026-06-16 | €130M financing from Claret Capital Partners for Phase 3 | POSITIVE — Funding secured | POSITIVE | | 2026-06-12 | EIB loan repayment, warrant buyback, new debt financing tranches | POSITIVE — Balance sheet management | POSITIVE | | 2026-06-09 | General Meeting preparatory documents & voting rights statements | NEUTRAL — Administrative | NEUTRAL |

Sentiment Assessment

Aggregate Sentiment: POSITIVE NEWS / BEARISH PRICE ACTION DIVERGENCE

  • Latest 2 news items (60% of recent coverage) are POSITIVE, focused on:

    • €130M funding commitment from institutional partner Claret Capital Partners
    • Proactive debt management: EIB loan repayment + warrant buyback + new financing tranches

  • Remaining 40% is NEUTRAL administrative announcements (shareholder meeting notices)

Critical Disconnect: Why Positive News Failed to Support Price

The 41.8% decline from 200-day MA ($4.98) to current price ($2.90) occurred despite positive financing announcements:

Possible Explanations:

  1. Dilution Concerns: €130M financing likely involves significant equity dilution; market pricing permanent shareholder base reduction
  2. Clinical Viability Questions: Positive financing may indicate Phase 3 costs higher than initially expected, raising efficacy/safety concerns
  3. Commercial Doubt: Market skeptical of Phase 3 success rate or eventual market size for Inventiva's pipeline
  4. Pre-announcement Decline: Price may have already collapsed on preliminary funding discussions; news reflected what market already priced
  5. Runway Insufficiency: Market may view €130M as inadequate runway given cash burn rate

Data Quality Note: News dates range June 9-16, 2026 (future dates in provided data) — dates appear speculative or from simulated scenario.

Catalyst Identification

Immediate Catalysts (1-7 days):

  • General Shareholder Meeting on 2026-06-30 — potential capital structure changes, board elections

Near-term Catalysts (1-4 weeks):

  • Phase 3 clinical trial progress updates or interim data
  • Clarification on €130M funding terms (timing of tranches, dilution percentage, use of proceeds)
  • Any management commentary on runway and burn rate

Medium-term Catalysts (1-3 months):

  • Phase 3 topline results (critical for valuation reset)
  • Additional financing updates if €130M insufficient
  • Potential partnership or out-licensing announcements

Market Narrative

Contradiction between Technical and News Signals — SEVERE

| Signal Type | Status | Message | |-------------|--------|---------| | News | POSITIVE | Company has secured funding, managing debt responsibly | | Price Action | SEVERE BEARISH | Market rejecting news, suggesting concerns beyond headlines | | Volume | BEARISH | Low volume on any bounces; heavy selling pressure persisting | | Technicals | OVERSOLD BUT BREAKING |

Generated
News
All IVA news →

IVA Options Activity & IV Rank

Volatility Metrics

Current IV: —
7-DTE IV: —
Expected Move: $4.03
7-DTE Move: $2.85
Days to Exp: 39 (2026-12-18)

Options Flow · All expiries

Call Volume: 973
Put Volume: 457
P/C Volume: 0.47
BULLISH
Call OI: 64,308
Put OI: 4,086
P/C OI: 0.064
Total OI: 68,394

ATM Options Pricing

ATM Call: $1.27
ATM Put: $2.75
Call %: 33.2%
Put %: 71.7%

Chain Summary

Chain Volume: 1,430
Chain OI: 68,394
Last Updated: 11/9/2026
Spread Scanner
Full Algorithm Docs ↗

Each spread is ranked by a composite score built in three stages. Full documentation →

Stage 1 — Base Score

score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Calendars: the long leg is valued at the short leg’s expiration (Black-Scholes at its current IV) across the range of prices the short leg’s IV implies, giving the best-case profit (R/R = that over the debit) and P(profit).

Stage 2 — Skew Adjustment (±25% cap)

RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.

Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
  • RSI <40 bullish / >60 bearish
  • MACD crossover + histogram trend
  • Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
  • Stochastic %K <20 / >80
  • Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
  • Blended ATR + straddle expected-move penalty
  • Bollinger Band signal (+ counter-trend penalty)
  • BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
  • IV rank ≥ 75 → strong boost for credit spreads
  • IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
  • Min open interest across all legs
  • OI < 100 → −0.10 · OI < 500 → −0.05

score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →

Scanning bull put, bear call, iron condor and calendar spreads…

Dealer Positioning
LOW γ vs HISTORY

Estimated net dealer gamma is at the 5th percentile of this name's own daily history, near the low end of its range. This describes current positioning; it is not a forecast or a trading signal.

Gamma percentile
5%
vs own history
GEX tilt
-0.46
OI-weighted, today
Vanna tilt
-0.94
δ-sensitivity to IV
Charm tilt
+0.99
δ-decay vs time
Vanna tilt -0.94: the estimated dealer exposure leans negative, so the modeled hedge would shift noticeably if implied volatility changed.
Charm tilt +0.99: the estimated dealer exposure leans positive, so the modeled hedge would shift noticeably as time passes and options approach expiry.

Net dealer gamma is an estimate of the aggregate gamma held by options market makers across this name's option chain, weighted by open interest. Dealer positions aren't public, so it uses a standard simplifying assumption: dealers are treated as long the calls and short the puts that are open. Actual dealer books can differ.

Gamma percentile ranks today's estimate against this name's own daily history, from 0% (the lowest reading on record) to 100% (the highest). Raw gamma scales with how much open interest a chain carries, so it isn't comparable across names; the percentile is. The badge marks the bottom 20% as low and the top 20% as high.

Tilts run from −1 to +1 and show how lopsided the estimated dealer exposure is. GEX tilt compares call gamma with put gamma. Vanna tilt describes how the hedge would shift if implied volatility changed, and charm tilt how it would shift with the passage of time.

This card describes estimated positioning and where it sits historically. It is not a forecast of price direction or volatility and not a trading signal. Market-wide view: Dealer positioning screener.

· 3 ATM contracts, 0k total OI
Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Metric:
Wing vs ATM
IV(put wing) − IV(ATM), in vol points

How much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.

  • Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
  • Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
  • Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
  • Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each side

Which side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.

  • Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
  • Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
  • Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
  • Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together

Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:

  • High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
  • Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
  • Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d —
— pts EXTREME
No data
30 DTE / 10d —
— pts EXTREME
No data

Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.

Volatility Surface

Loading the implied volatility surface…

Volatility Smile

Loading the implied volatility smile…

IV Rank (7 DTE)
IV Rank (30 DTE)
Straddle Price (30 DTE)$4.03Nov 9
Beta Analysis

Risk Metrics

Beta: 0.8974
Alpha: 5.35%
Correlation: 0.1885
R-Squared: 3.6%
Stock Volatility: 65.6%
Market Volatility: 13.8%

Analysis Details

Benchmark: SPY
Data Points: 251
Period: 252 trading days
Interpretation:
Moderate volatility - stock generally follows market
Beta & Alpha Over Time
Notable investors who own IVA
3 of 37 tracked investors
InvestorValueShare of their portfolioRankQ/Q sharesSource
Millennium Management Hedge fund
Izzy Englander
$13.3M
0.01%
#1388 of 3716+17.6%13F
Citadel Hedge fund
Ken Griffin
$6.7M
0.00%
#1865 of 6285+2647.6%13F
Point72 Hedge fund
Steve Cohen
$6.4M
0.01%
#909 of 1945+76.0%13F

Hedge funds, activists, holding companies and family offices we track, from their latest 13F (quarter-end value) and Form 4 filings in the last 3 years. Family offices · all institutions

IVA Institutional Ownership (13F)

Filings for 2026-06-30 · 21 already for 2026-09-30

Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.

  • Shares — long equity positions in this name, aggregated across share classes.
  • Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
  • % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
  • Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.

Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.

90 filers85,990,521 shares$323.73M value
# Filer Shares Value % of Total % of Float Period
1 Caligan Partners LP 8,163,191 $30.86M 9.53% — 2026-06-30
2 Samsara BioCapital, LLC 6,314,805 $23.87M 7.37% — 2026-06-30
3 Paradigm Biocapital Advisors LP 4,000,000 $15.12M 4.67% — 2026-06-30
4 ADAR1 Capital Management, LLC 3,606,656 $13.63M 4.21% — 2026-06-30
5 Andera Partners 3,633,181 $13.41M 4.14% — 2026-09-30
6 Millennium Management LLC Custodian 3,512,174 $13.28M 4.10% — 2026-06-30
7 Aberdeen Group plc 3,145,711 $11.61M 3.59% — 2026-09-30
8 Nantahala Capital Management, LLC 2,686,393 $10.15M 3.14% — 2026-06-30
9 Trails Edge Capital Partners, LP 2,657,997 $10.05M 3.10% — 2026-06-30
10 Franklin Resources, Inc. Custodian 2,642,611 $9.99M 3.09% — 2026-06-30
11 Squadron Capital Management LLC 2,435,000 $9.20M 2.84% — 2026-06-30
12 Woodline Partners LP 2,323,149 $8.78M 2.71% — 2026-06-30
13 UBS Group AG Custodian 2,305,192 $8.71M 2.69% — 2026-06-30
14 BOOTHBAY FUND MANAGEMENT, LLC 2,003,782 $7.57M 2.34% — 2026-06-30
15 Patient Square Capital LP 1,967,171 $7.44M 2.30% — 2026-06-30
16 NEXTBio Capital Management LP 1,787,984 $6.76M 2.09% — 2026-06-30
17 Citadel Advisors LLC Custodian 1,784,566 $6.75M 2.08% — 2026-06-30
18 Ameriprise Financial, Inc. Custodian 1,697,148 $6.42M 1.98% — 2026-06-30
19 Point72 Asset Management, L.P. 1,683,012 $6.36M 1.97% — 2026-06-30
20 Integral Health Asset Management, LLC 1,520,000 $5.75M 1.77% — 2026-06-30
21 Yu Fan 1,500,000 $5.67M 1.75% — 2026-06-30
22 NEA Management Company, LLC 1,462,586 $5.53M 1.71% — 2026-06-30
23 STEMPOINT CAPITAL LP 1,426,320 $5.39M 1.67% — 2026-06-30
24 Propel Bio Management, LLC 1,281,212 $4.84M 1.50% — 2026-06-30
25 KINGDON CAPITAL MANAGEMENT, L.L.C. 1,270,000 $4.80M 1.48% — 2026-06-30
2 filers$111.07K notional
# Filer Notional Value % of Total Period
1 Barclays PLC Custodian $103.69K 93.36% 2026-09-30
2 Belvedere Trading LLC $7.38K 6.64% 2026-09-30
# Filer Notional Value % of Total Period

IVA Insider Trading (Form 4)

Latest: 2010-10-13
Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
Filed Reporter Role Action Shares Avg Price Net $ Link
2010-10-13 Joseph C Visconti CEO, President, Chairman Sell (S) +24,000 $0.14 $3.4K EDGAR
2010-07-12 Joseph C Visconti CEO, President, Chairman Sell (S) +24,000 $0.14 $3.4K EDGAR
2008-12-10 Joseph C Visconti President & CEO Buy (P) +45,500 $0.15 $6.7K EDGAR
2008-11-14 Joseph C Visconti President & CEO Buy (P) +67,100 $0.18 $12.1K EDGAR
2008-09-16 Joseph C Visconti President & CEO Buy (P) +19,300 $0.25 $4.8K EDGAR
2007-11-28 Joseph C Visconti President and CEO Buy (P) +16,800 $0.58 $9.7K EDGAR
2007-08-29 Joseph C Visconti President and CEO Buy (P) +500 $1.00 $500 EDGAR
2007-08-20 Joseph C Visconti President and CEO Buy (P) +4,500 $1.95 $8.8K EDGAR
2007-08-13 Joseph C Visconti President and CEO Buy (P) +236,507 $3.50 $827.8K EDGAR
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.
ETF Holders
10 ETFs hold IVA
10 shown · $6.02M total exposure · 0.00% AUM-weighted avg weight
# ETF Provider Weight $ Exposure ETF AUM As Of
1 IEFA iShares Core MSCI EAFE ETF iShares (BlackRock) 0.00% $2.7M $187.1B 2026-11-06
2 SCZ iShares MSCI EAFE Small-Cap ETF iShares (BlackRock) 0.01% $1.3M $12.6B 2026-11-06
3 SURI Simplify Propel Opportunities ETF Nport 1.53% $1.2M — 2026-06-30
4 GWX State Street® SPDR® S&P® International Small Cap ETF SPDR (State Street) 0.05% $475,522 $896.1M 2026-11-05
5 MEDI Harbor Health Care ETF Nport 0.37% $152,302 — 2026-07-31
6 ISCF iShares International Small-Cap Equity Factor ETF iShares (BlackRock) 0.01% $72,087 $697.6M 2026-11-06
7 APIE ActivePassive International Equity ETF Nport 0.00% $47,179 — 2026-08-31
8 IEUS iShares MSCI Europe Small-Cap ETF iShares (BlackRock) 0.02% $38,836 $165.5M 2026-11-06
9 SPEU State Street® SPDR® Portfolio Europe ETF SPDR (State Street) 0.00% $29,673 $717.1M 2026-11-05
10 WSML iShares MSCI World Small-Cap ETF iShares (BlackRock) 0.00% $29,643 $656.6M 2026-11-06
Fundamentals

Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.

Metrics
  • Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
  • Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
  • Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
  • Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
  • Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
  • YoY growth — compare to the same quarter a year earlier to remove seasonality.
  • Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
  • Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.

TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.

Trailing P/E
—
TTM Diluted EPS
—
TTM Revenue
—
TTM Net Income
—
TTM Op. Cash Flow
—

IVA vs Peers

Related companies, largest first
Company Market cap P/E Revenue growth YTD IV rank
LLY Eli Lilly & Co. $1.21T 46.0 +45.5% +31.2% 26
CORT Corcept Therapeutics Inc. $7.9B 59.0 +30.0% +96.1% 100
CLDX Celldex Therapeutics, Inc $2.3B — −93.9% +15.7% 10
IVA Inventiva S.A. American Depository Share $916M — — −19.4% 35
ACHV Achieve Life Sciences, Inc. $693M — — +34.6% 47
DCTH Delcath Systems Inc $518M 1965.5 +35.8% +97.5% 9
PHAT Phathom Pharmaceuticals, Inc. Common Sto $427M — +86.8% −65.9% 5
ABEO Abeona Therapeutics Inc. Common Stock $238M — +6280.0% −50.9% 30
MIST Milestone Pharmaceuticals Inc. Common Sh $95M — — −61.9% —
Peer median $605M 59.0 +40.6% +23.5% 26

P/E uses the latest reported trailing-12-month diluted EPS; "—" means no positive earnings or no data.

Short Interest & Float

Regulatory short-interest reports publish on a bi-weekly settlement cadence; short-volume is reported daily by the trade-reporting facilities. Float is derived from insider-ownership filings.

Metric definitions
  • Short Interest — total shares currently sold short as of the settlement date. Lags real time by ~8 business days.
  • SI % of Float — short interest / free float. The key crowding metric.
  • Days to Cover — short interest / avg daily volume. How many full trading days it would take shorts to buy back. High DTC + catalyst = squeeze fuel.
  • Short Vol Ratio — today's short-sale volume / total volume. Intraday selling pressure proxy (not the same as short interest).
  • Free Float — shares available for public trading (total shares minus insider / restricted).
  • Float % — free float / shares outstanding. <50% = tightly held, more prone to squeezes.
How to read the signals
  • SI % of Float < 5% — typical, no particular signal.
  • 5–15% — elevated; watch for catalysts (earnings, guidance, macro).
  • 15–30% — heavily shorted; tight-float names in this range have produced notable squeezes historically.
  • >30% — extreme; borrow is likely expensive and squeeze risk is material.
  • Days to Cover > 5 combined with high SI% amplifies squeeze potential.
History chart
  • Trend matters more than level. Rapidly rising short interest often precedes negative catalysts or heavy hedging.
  • A sudden drop in SI after a rally may indicate a squeeze in progress.

Short interest is reported mid-month and end-of-month; short volume is daily.

Short Interest
8.15M
SI % of Float
3.41%
Days to Cover
2.75
Short Vol Ratio
17.0%
Free Float
—
Float %
—
Short interest 2026-10-15 • Short volume 2026-11-06